Top

Published in:

01-06-2020 | Opioids | Original Paper

A Latent Class Analysis of HIV Risk Factors Among Men and Women with Opioid Use Disorder in Pre-trial Detention

Authors: Mary M. Mitchell, Jan Gryczynski, Shannon G. Mitchell, Sharon M. Kelly, Kevin E. O’Grady, Laura B. Monico, Robert P. Schwartz

Published in: AIDS and Behavior | Issue 6/2020

Abstract

Adults entering pre-trial detention who inject drugs are at high risk for acquiring HIV/AIDS. In the current study, we examined pre-incarceration HIV risk behaviors among 114 people with opioid use disorder who inject drugs. Participants were recruited from the Baltimore City Detention Center as part of a randomized controlled trial of pre-release methadone treatment. Using latent class analysis, we found three separate latent classes, which we identified as the sex exchange class (14.2%), drug equipment sharing class (36.8%) and lower risk class (49.0%). Women in the sex exchange class (n = 16) reported having multiple male partners and selling sex for money or drugs; however, this group also reported more consistent condom use and less frequent injection drug and equipment sharing than participants in the drug equipment sharing class. Our findings highlight distinct profiles of jail detainees with OUD based on their risks for HIV, and could inform more targeted interventions for each group.

Clinical Trials Registration: Clinicaltrials.gov NCT 02334215

Collica K. The prevalence of HIV peer programming in American prisons: an opportunity wasted. J Correct Health Care. 2007;13(4):278–88.CrossRef

Adams LM, Kendall S, Smith A, Quigley E, Stuewig JB, Tangney JP. HIV risk behaviors of male and female jail inmates prior to incarceration and one year post-release. AIDS Behav. 2013;17(8):2685–94. https://doi.org/10.1007/s10461-011-9990-2.CrossRefPubMedPubMedCentral

Harawa N, Adimora A. Incarceration, African Americans and HIV: advancing a research agenda. J Natl Med Assoc. 2008;100(1):57–62.CrossRefPubMed

Abiona TC, Balogun JA, Adefuye AS, Sloan PE. Pre-incarceration HIV risk behaviours of male and female inmates. Int J Prison Health. 2009;5(2):59–70. https://doi.org/10.1080/17449200902880524.CrossRefPubMed

Conklin TJ, Lincoln T, Tuthill RW. Self-reported health and prior health behaviors of newly admitted correctional inmates. Am J Public Health. 2000;90(12):1939–41.CrossRefPubMedPubMedCentral

Strathdee SA, West BS, Reed E, Moazen B, Azim T, Dolan K. Substance use and HIV among female sex workers and female prisoners: risk environments and implications for prevention, treatment, and policies. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S110–7. https://doi.org/10.1097/QAI.0000000000000624.CrossRefPubMedPubMedCentral

Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94(7):1218–23.CrossRefPubMedPubMedCentral

Vlahov D, Brewer F, Munoz A, Hall D, Taylor E, Polk BF. Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985–1987. J Acquir Immune Defic Syndr. 1989;2(3):283–90.PubMed

Alarid LF, Hahl JM. Seroconversion risk perception among jail populations: a call for gender-specific HIV prevention programming. J Correct Health Care. 2014;20(2):116–26. https://doi.org/10.1177/1078345813518631.CrossRefPubMed

10.

Morrow KM, The Project START Study Group 1. HIV, STD, and hepatitis risk behaviors of young men before and after incarceration. AIDS Care. 2009;21:235–43.CrossRefPubMed

11.

Zhen Zeng, Jail Inmates in 2016 U.S. Department of Justice Office of Justice Programs Bureau of Justice Statistics. February 2018, NCJ 251210.

12.

E. Ann Carson, Bureau of Justice Statistics | Office of Justice Programs | U.S. Department of Justice. Prisoners in 2016. Summary | NCJ 251149 | January 2018.

13.

Cotten-Oldenburg NU, Jordan BK, Martin SL, Kupper L. Women inmates’ risky sex and drug behaviors: are they related? Am J Drug Alcohol Abuse. 1999;25(1):129–49.CrossRefPubMed

14.

Anglin MD, Brown BS, Dembo R, Leukefeld C. Criminality and addiction: selected issues for future policies, practice, & research. J Drug Issues. 2009;39(1):89–99.CrossRef

15.

Epperson MW, Khan MR, Miller DP, Perron BE, El-Bassel N, Gilbert L. Assessing criminal justice involvement as an indicator of human immunodeficiency virus risk among women in methadone treatment. J Subst Abuse Treat. 2010;38(4):375–83. https://doi.org/10.1016/j.jsat.2010.03.004.CrossRefPubMedPubMedCentral

16.

Altice FL, Marinovich A, Khoshnood K, Blankenship KM, Springer SA, Selwyn PA. Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection. J Urban Health. 2005;82(2):312–26.CrossRefPubMedPubMedCentral

17.

Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–91. https://doi.org/10.1111/j.1360-0443.2006.01316.x.CrossRefPubMed

18.

Kopetz C, Pickover A, Magidson JF, Richards JM, Iwamoto D, Lejuez CW. Gender and social rejection as risk factors for engaging in risky sexual behavior among crack/cocaine users. Prev Sci. 2014;15(3):376–84. https://doi.org/10.1007/s11121-013-0406-6.CrossRefPubMedPubMedCentral

19.

Johnson MW, Herrmann ES, Sweeney MM, LeComte RS, Johnson PS. Cocaine administration dose-dependently increases sexual desire and decreases condom use likelihood: the role of delay and probability discounting in connecting cocaine with HIV. Psychopharmacology. 2017;234(4):599–612. https://doi.org/10.1007/s00213-016-4493-5.CrossRefPubMed

20.

Schwartz RP, Kelly SM, Mitchell SG, Dunlap L, Zarkin GA, Sharma A, et al. Interim methadone and patient navigation in jail: rationale and design of a randomized clinical trial. Contemp Clin Trials. 2016;49:21–8. https://doi.org/10.1016/j.cct.2016.06.002.CrossRefPubMedPubMedCentral

21.

Metzger, D., et al. “The risk assessment battery (RAB): Validity and reliability.” Sixth annual meeting of national cooperative vaccine development group for AIDS. University of Pennsylvania, Center for Studies on Addition, Philadelphia: PA; 1993.

22.

McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The addiction severity index. J Nerv Ment Dis. 1980;168(1):26–33.CrossRefPubMed

23.

McCutcheon A. Latent class analysis. Los angeles: Sage; 1987.CrossRef

24.

Collins LM, Lanza S. Latent class and latent transition analysis: With applications in the social, behavioral, and health sciences. Hoboken: Wiley; 2010.

25.

Reboussin BA, Song EY, Shrestha A, Lohman KK, Wolfson M. A latent class analysis of underage problem drinking: evidence from a community sample of 16–20 year olds. Drug Alcohol Depend. 2006;83(3):199–209. https://doi.org/10.1016/j.drugalcdep.2005.11.013.CrossRefPubMed

26.

Muthén L, Muthén B. Mplus user’s guide (8th Ed.). Los Angeles, CA: Muthén & Muthén; 1998–2017.

27.

Akaike H. Akaike’s information criterion: international encyclopedia of statistical science. Berlin: Springer; 2011. p. 25.

28.

Sclove L. Applications of model-selection criteria to some problems in multivariate analysis. Psychometricka. 1987;52:333–43.CrossRef

29.

McLachlan G, Peel D. Finite mixture models. New York: Wiley; 2000.CrossRef

30.

Muthen B. Latent variable analysis: growth mixture modeling and related techniques for longitudinal data. In: Kaplan D, editor. The sage handbook of quantitative methodology for the social sciences. Thousand Oaks: Sage; 2004. p. 345–68.

31.

Nylund K, Asparouhov T, Muthen B. Deciding on the number of classes in latent class analysis and growth mixture modeling: a monte carlo simulation study. Struct Equ Model. 2007;14(4):535–69.CrossRef

32.

Henson JM, Reise SP, Kim KH. Detecting mixtures from structural model differences using latent variable mixture modeling: a comparison of relative model fit statistics. Struct Equ Model. 2007;14(2):202–26.CrossRef

33.

Chung H, Flaherty B, Schafer J. Latent class logistic regression: application to marijuana use and attitudes among high school seniors. J R Stat Soc. 2006;169(4):723–43.CrossRef

34.

Asparouhov, T., & Muthen, B. Auxiliary variables in mixture modeling: A 3-step approach using Mplus; 2013. https://statmodel.com/examples/webnotes/AuxMixture_submitted_corrected_webnote. Accessed 1 Nov 2018.

35.

Boyer CB, Greenberg L, Chutuape K, Walker B, Monte D, Kirk J, et al. Exchange of sex for drugs or money in adolescents and young adults: an examination of sociodemographic factors, HIV-related risk, and community context. J Community Health. 2017;42(1):90–100. https://doi.org/10.1007/s10900-016-0234-2.CrossRefPubMedPubMedCentral

36.

Marshall BD, Shannon K, Kerr T, Zhang R, Wood E. Survival sex work and increased HIV risk among sexual minority street-involved youth. J Acquir Immune Defic Syndr. 2010;53(5):661–4. https://doi.org/10.1097/QAI.0b013e3181c300d7.CrossRefPubMedPubMedCentral

37.

Davey-Rothwell MA, Latkin CA. Gender differences in social network influence among injection drug users: perceived norms and needle sharing. J Urban Health. 2007;84(5):691–703. https://doi.org/10.1007/s11524-007-9215-1.CrossRefPubMedPubMedCentral

38.

El-Bassel N, Wechsberg WM, Shaw SA. Dual HIV risk and vulnerabilities among women who use or inject drugs: no single prevention strategy is the answer. Curr Opin HIV AIDS. 2012;7(4):326–31. https://doi.org/10.1097/COH.0b013e3283536ab2.CrossRefPubMedPubMedCentral

39.

Bekker LG, Johnson L, Cowan F, Overs C, Besada D, Hillier S, et al. Combination HIV prevention for female sex workers: what is the evidence? Lancet. 2015;385(9962):72–87. https://doi.org/10.1016/S0140-6736(14)60974-0.CrossRefPubMed

40.

Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction. 1993;88(4):517–26.CrossRefPubMed

41.

Walters SM, Rivera AV, Reilly KH, Anderson BJ, Bolden B, Wogayehu A, et al. Exchange sex among persons who inject drugs in the New York metropolitan area: the importance of local context gender and sexual identity. AIDS Behav. 2018;22(9):2773–87. https://doi.org/10.1007/s10461-018-2039-z.CrossRefPubMed

42.

Farel CE, Parker SD, Muessig KE, Grodensky CA, Jones C, Golin CE, Wohl DA. Sexuality, sexual practices, and HIV risk among incarcerated African-American women in North Carolina. Women’s Health Issues. 2013;23(6):e357–64.CrossRefPubMedPubMedCentral

43.

Gowing L, Farrell M, Bornemann R, Sullivan LE, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008. https://doi.org/10.1002/14651858.CD004145.pub3.CrossRefPubMed

44.

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O’Brien CP. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42. https://doi.org/10.1056/NEJMoa1505409.CrossRefPubMedPubMedCentral

45.

Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998;113(Suppl 1):75.PubMedPubMedCentral

46.

Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D. Drug abuse treatment success among needle exchange participants. Public Health Rep. 1998;113(Suppl 1):129.PubMedPubMedCentral

47.

Heimer, R., Eicher, A., Eno, R., Greaves, S., Kamina, A., Singh, M., & Massaro, S. (1996) Needle exchange programs as a conduit to drug treatment: the New Haven experience. In 11th International Conference on AIDS, Vancouver, Canada.

48.

Underhill K, Dumont D, Operario D. HIV prevention for adults with criminal justice involvement: a systematic review of HIV risk-reduction interventions in incarceration and community settings. Am J Public Health. 2014;104:e27–53. https://doi.org/10.2105/AJPH.2014.302152.CrossRefPubMedPubMedCentral

49.

Mericle AA, Mahoney E, Korcha R, Delucchi K, Polcin DL. Sober living house characteristics: a multilevel analyses of factors associated with improved outcomes. J Subst Abuse Treat. 2019;98:28–38.CrossRefPubMed

50.

Abad N, Baack BN, O’Leary A, Mizuno Y, Herbst JH, Lyles CM. A systematic review of HIV and STI behavior change interventions for female sex workers in the United States. AIDS Behav. 2015;19(9):1701–19.CrossRefPubMed

51.

Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS (London, England). 2014;28(10):1509.CrossRefPubMedCentral

52.

Brafford LJ, Beck KH. Development and validation of a condom self-efficacy scale for college students. J Am Coll Health. 1991;39(5):219–25.CrossRefPubMed

53.

Needle RH, Burrows D, Friedman SR, Dorabjee J, Touzé G, Badrieva L, Latkin C. Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users. Int J Drug Policy. 2005;16:45–57.CrossRef

Title: A Latent Class Analysis of HIV Risk Factors Among Men and Women with Opioid Use Disorder in Pre-trial Detention
Authors: Mary M. Mitchell
Jan Gryczynski
Shannon G. Mitchell
Sharon M. Kelly
Kevin E. O’Grady
Laura B. Monico
Robert P. Schwartz
Publication date: 01-06-2020
Publisher: Springer US
Keywords: Opioids
Opioids
Human Immunodeficiency Virus
Published in: AIDS and Behavior / Issue 6/2020
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-019-02726-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Alcohol Use and Antiretroviral Therapy Non-Adherence Among Adults Living with HIV/AIDS in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

Effects of Depression, Stigma and Intimate Partner Violence on Postpartum Women’s Adherence and Engagement in HIV Care in Kenya

Correlates of HIV Transmission Behaviors and HIV Testing in Predominately African American/Black Women with High-Risk Male Sex Partners

Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysis

Prevalence of Non-medical Amphetamine Use Among Men with Diagnosed HIV Infection Who Have Sex with Men in the United States, 2015–2016

Characteristics of Sex Events, Partners, and Motivations and Their Associations with HIV-Risk Behavior in a Daily Diary Study of High-Risk Men Who Have Sex with Men (MSM)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials